Note:below is the rough translation form German to English
I thought this was worthwhile posting to show how important the listing is in Europe.it makes some interesting points!
cheers
Birdseye
05:06:12
DGAP-NEWS
Prima Biomed LtdShs
From source: Finanzen.net / Aktiencheck.de AG
DGAP-News: Prima BioMed today also listed in the Entry Standard DGAP-News: Prima Biomed Ltd.
------------------- ----------------------- Note by the company on NASDAQ and ASX in Sydney Sydney
/ Leipzig, 05 June 2012 - The Australian health care company Prima BioMed Ltd. has today, 5 June 2012, also listed in the Entry Standard derFrankfurter Stock Exchange. This is the stock market listing in Sydney (ASX) and added to the NASDAQ.
In Frankfurt will be the 16th since April on NASDAQ notiertenADRs, American Depositary Receipts (ISIN US74154B2034) traded jeweilsein ADR represents 30 Prima BioMed shares. The listing process was accompanied by the inDeutschland Concord Capital AG.
The listing in the Entry Standard Prima BioMed contributes to the growing importance of Germany and Europe in the global strategy of zurEntwicklung CVacTM (vaccine for the treatment of ovarian cancer) account.
Currently enrolling CANVAS has begun. Should CANVAS (Cancer Vaccine Study) is a clinical trial for CVacTM a maintenance therapy, Prima BioMed against ovarian cancer (ovarian cancer) based on an autologous (autologous) Immuntherapie
.Die study include 800 patients at up to 150 medical centers in 22Ländern in Europe and Australia . The first patient was admitted vorwenigen weeks already in the U.S. in CANVAS.
Prima BioMed is already in Germany with a subsidiary represented inLeipzig and works in close cooperation with the team desFraunhofer Institute for Cell Therapy and Immunology (IZI) together .
Diein advanced clinical stage of development CVacTMwird located in Germany also supported by the Development Bank of Saxony. Wants
The listing in the Entry Standard Prima BioMed European investors have had the ability to become involved in PrimaBioMed at the same time increased transparency level.
With a market capitalization of currently around 120 million euros converted PrimaBioMed will belong to the time of inclusion in the Entry Standard to the larger values of the segment
About CVacTM for the treatment of ovarian cancer Prima BioMed's main product is CVacTM against ovarian cancer as a maintenance therapy. CVacTM to the treatment of ovarian cancer on the basis of one body's own immune therapy serve to delay the relapse, dieMetastasenentwicklung control and progression-free and is designed to improve dasGesamtüberleben.
The need for novel therapy against ovarian cancer is high.
Ovarian cancer is one of the highest cancer mortality rate mitder and currently there are no Medikamenteauf receive therapeutic basis.
The company has recently been the inclusion of patients for the Phase IIb trial completed derCVacTM in the U.S. under the supervision of the U.S. Food and Drug Administration (FDA) and is currently in the derStartphase Cancer Vaccine Study (CANVAS). CANVAS is a randomized, double-blind, placebo-controlled study jeweilsan several medical centers in Europe, Australia and is USAdurchgeführt.
The Phase IIb and CANVAS are aimed at the Wirksamkeitvon CVacTM bestätigen.
Das main goal of Prima BioMed, the regulatory approval and commercialization of CVacTM.
About Prima BioMed Prima BioMed
a global biotech company headquartered inAustralien. The company specializes in cancer research on technologies inquality personalized biotherapeutics. Prima BioMed'sHauptprodukt the candidate therapy for the treatment is CVacTM vonEierstockkrebs.
CVacTM has already successfully undergone two clinical trials. The long-term goal of Prima BioMed is the world Bank The development of commercial technologies and cancer treatment programs.
More information, see www.primabiomed.com.au.
End of Corporate News
-----------------------------------------------
http://www.morgenpost.de/newsticker/finanzen_nt/Hugin_DGAP_News_nt/article106416027/Prima-Biomed-LtdShs.html
(20min delay)